Kombinatsiya CJC-1295/Ipamorelin: Obzor issledovaniy i predposylki

Kombinatsiya CJC-1295 i Ipamorelinma otnositsya k naibolee chasto obsuzhdaemym peptidnym stekam v issledovaniyakh GH. Oba peptida stimuliruyut vysvobozhdenie gormona rosta, no cherez razlichnye retseptornye sistemy. Etot komplementarnyy mekhanizm yavlyaetsya prichinoy, po kotoroy kombinatsiya izuchalas v issledovatelskikh usloviyakh.

V etoy statie obobshchayutsya dostupnye dannye: mekhanizmy deystviya, farmakokineticheskye razlichiya, dannye o sinergii i profili bezopasnosti oboikh peptidov.

CJC-1295/Ipamorelin (No-DAC)growth

Смесь 2-в-1 для гормона роста: CJC-1295 no-DAC (Modified GRF 1-29, 5 мг) + Ипаморелин (5 мг) в одном флаконе. Компонент CJC-1295 - это короткодействующий вариант без DAC (период полураспада около 30 минут), а не длительно действующая DAC-форма. Естественная стимуляция гормона роста через два механизма.

CJC-1295: Analog GHRH s prodlennym deystviem

CJC-1295 - sinteticheskiy analog gormona, vysvobozhdayushchego gormon rosta (GHRH). On sostoit iz pervykh 29 aminokislot naturalnogo GHRH s chetyrmya aminokislotnymi substitutsiyami, kotorye obespechivayut ustoychivost k degradatsii dipeptidilpeptidazoy-4 (DPP-4).

S DAC i bez DAC

Klyuchevoe prakticheskoe razlichie kasaetsya varianta:

• CJC-1295 s DAC (Drug Affinity Complex): Komponent DAC svyazyvaetsya s albuminom v krovi, udlinyaya period poluraspada do priblizitelno 6-8 dney. Odnokratnaya inektsiya mozhet povyshat urovni GH v techenie neskolkikh dney.
• CJC-1295 bez DAC (takzhe nazyvaemyy Mod GRF 1-29): Period poluraspada okolo 30 minut. Trebuet mnogokratnogo ezhednvnogo dozirovaniya, no proizvdit bolee pulsatilnyy pattern vysvobozhdeniya.

Klinicheskie dannye

Teichman et al. (2006) opublikovali klyuchevoe klinicheskoe issledovanie CJC-1295 s DAC v Journal of Clinical Endocrinology & Metabolism. V etom randomizirovannom, platsebo-kontroliruemom, dvoynom slepom issledovanii u zdorovykh vzroslykh (21-61 god) odnokratnaya podkozhnaya inektsiya proizvela:

• Dozozavisimye povysheniya GH v 2-10 raz v techenie 6 dney ili dolee
• Povysheniya IGF-1 v 1,5-3 raza v techenie 9-11 dney
• Otsenochnyy period poluraspada: 5,8-8,1 dney
• Svidetelstva kumulyativnogo effekta pri povtornom dozirovanii

Avtory opisali vvedenie kak bezopasnoe i khorosho perenosimoe, osobenno pri dozakh 30 ili 60 mkg/kg. Soobshchennye pobochnye effekty byli legkimi reaktsiyami v meste inektsii.

Ipamorelin: Selektivnyy agonist retseptora grelina

Ipamorelin - pentapeptid, deystvuyushchiy na retseptor grelina (GHS-R1a) somatotropnykh kletok gipofiza. On prinadlezhit k klassu peptidov, vysvobozhdayushchikh gormon rosta (GHRP), no otlichaetsya ot bolee starykh predstaviteley znachitelno bolee selektivnym profilem.

Selektivnost kak otlichitelnaya kharakteristika

Raun et al. (1998) opisali Ipamorelin v European Journal of Endocrinology kak "pervyy selektivnyy sekretagog gormona rosta". Klyuchevoe nablyudenie:

• Ipamorelin vysvobodil GH bez znachitelnogo povysheniya AKTH ili kortizola vyshe kontrolnykh urovney GHRH
• Dazhe pri dozakh, prevyshayushchikh v 200 raz ED50 dlya vysvobozhdeniya GH, urovni kortizola ostavalsi stabilnymi
• Otsutstvie znachitelnogo vliyaniya na FSH, LH, prolaktin ili TSH

Dlya sravneniya: GHRP-6 i GHRP-2 proizvodyat izmerimye povysheniya AKTH i kortizola pri ekvivalentnykh dozakh, stimuliruyushchikh GH. Eti pobochnye effekty ogranichivayut ikh ispolzovanie v opredelennykh issledovatelskikh kontekstakh.

Sinergiya: GHRH + GHRP

Kombinatsiya analoga GHRH s GHRP ne yavlyaetsya novoy kontseptsiey. Bowers et al. opisali eshche v 1991 godu v Endocrinology, chto GHRP stimuliruet vysvobozhdenie GH cherez nezavisimyy, komplementarnyy mekhanizm - otdelno ot retseptora GHRH i nezavisimo ot opiatnykh retseptorov.

Dva otdelnykh signalnykh puti

Sinergisticheskiy effekt voznikaet pri odnovremennoy aktivatsii dvukh razlichnykh retseptornykh sistem:

1. Retseptor GHRH (aktivirovannyy CJC-1295): Stimuliruet signalnuyu kaskadu cAMP v somatotropnykh kletkakh
2. GHS-R1a (aktivirovannyy Ipamorelinmom): Stimuliruet kaskadu fosfolipazy C i vnutrikletochnoe vysvobozhdenie kaltsiya

Eti otdelnye vnutrikletochnye signalnye puti skhodyatsya pri sekretsii GH, proizvdya vmeste bolee silnyy otvet, chem kazhdyy put v otdelnosti.

Kolichestvennye dannye

Veldhuis et al. (2009) sistematicheski issledovali determinanty sinergii GHRH-GHRP v American Journal of Physiology. Osnovnye rezultaty:

• Sovmestnoe vvedenie proizvelo v 2-4 raza bolshuyu AUC GH (ploshchad pod krivoy) po sravneniyu s kazhdym soedineniyem v otdelnosti
• Effekt byl ot additivnogo do sinergisticheskogo v zavisimosti ot vremeni
• Povysheniya IGF-1 byli priblizitelno na 20-30% vyshe, chem pri odnorazovom vvedenii

Eti dannye otnosyatsya k obshchey kombinatsii GHRH+GHRP. Spetsificheskie klinicheskie issledovaniya tochnoy kombinatsii CJC-1295 s Ipamorelinmom ogranicheny. Perenosimost vytekayet iz obshchey retseptornoy farmakologii.

DAC ili bez DAC: Chto vazhno dlya issledovaniy?

Vybor varianta CJC-1295 imeet pryamye posledstviya dlya dizayna issledovaniya:

Parametr	CJC-1295 s DAC	CJC-1295 bez DAC (Mod GRF 1-29)
Period poluraspada	6-8 dney	ok. 30 minut
Pattern vysvobozhdeniya GH	Postoyannye povyshennyy bazalnyy uroven	Pulsatilnyy
Chastota dozirovaniya	1-2 raza v nedelyu	2-3 raza v den
Fiziologicheskoe skhodstvo	Menee fiziologichnyy	Blizhe k estestvennomu patternu

Variant DAC proizvodit ustoychivoe povyshenie GH, kotoroe ne sootvetstvuet estestvennomu pulsatilnomu patternu. Dlya issledovatelskikh voprosov, gde fiziologicheskaya pulsatilnost vazhna, chasto predpochitaetsya variant bez DAC.

Odnako issledovanie Ionescu & Bhatt (2006) pokazalo, chto pulsatilnaya sekretsiya GH sokhranmayetsya dazhe pri nepreryvnoy stimulyatsii CJC-1295 DAC - endogennaya somatostatinovaya regulyatsiya, po-vidimomu, ostaetsya funktsionalnoy.

Profil bezopasnosti

CJC-1295

Dannye Teichmana et al. (2006) ne pokazali sereznykh nezhelatelnykh yavleniy v issledovannykh diapazonakh doz (30-60 mkg/kg). Soobshchennye legkie pobochnye effekty vklyuchali:

• Reaktsii v meste inektsii (pokrasnenie, otek)
• Prekhodyashchie prilivy
• Legkaya retentsiya zhidkosti

Ipamorelin

Ipamorelin opisyvaetsya v literature kak khorosho perenosimyy. Naibolee chasto soobshchaemye legkie effekty:

• Golovnye boli
• Prekhodyashchaya ustalost
• Legkaya toshnota

Otsutstvie znachitelnykh povysheniy kortizola i prolaktina predstavlyayet preimushchestvo bezopasnosti pered drugimi GHRP.

Rezyume issledovaniy

Kombinatsiya CJC-1295/Ipamorelin ispolzuet komplementarnuyu retseptornuyu farmakologiyu signalnykh putey GHRH i GHRP. Dannye podderzhivayut sleduyushchie klyuchevye punkty:

• CJC-1295 prodlevayet aktivatsiyu retseptora GHRH i dozozavisimo povysil GH i IGF-1 v klinicheskikh issledovaniyakh (Teichman et al., 2006)
• Ipamorelin - naibolee selektivnyy izvestnyy GHRP s minimalnym vliyaniem na kortizol i prolaktin (Raun et al., 1998)
• Kombinatsii GHRH+GHRP proizvodyat sinergisticheskie otvety GH s v 2-4 raza bolshey AUC, chem otdelnye soedineniya (Veldhuis et al., 2009)
• Oba peptida prodemonstrirovali blagopriyatnyy profil bezopasnosti v kratkosrochnykh issledovaniyakh

Issledovaniya etoy kombinatsii ostayutsya aktivnymi, no dolgosrochnye dannye i krupnye randomizirovannye issledovaniya otsutstvuyut. Dlya tekushchego sostoyaniya znaniy tsitiruemye publikatsii obespechivayut solidnuyu osnovu.

Chasto zadavaemye voprosy

Zakazat CJC-1295/Ipamorelin

CJC-1295/Ipamorelin (No-DAC)growth

Смесь 2-в-1 для гормона роста: CJC-1295 no-DAC (Modified GRF 1-29, 5 мг) + Ипаморелин (5 мг) в одном флаконе. Компонент CJC-1295 - это короткодействующий вариант без DAC (период полураспада около 30 минут), а не длительно действующая DAC-форма. Естественная стимуляция гормона роста через два механизма.

Ssylki

1. Teichman SL et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab, 91(3), 799-805.
2. Raun K et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol, 139(5), 552-561.
3. Bowers CY et al. (1991). On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology, 128(4), 2027-2035.
4. Veldhuis JD et al. (2009). Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Endocrinol Metab, 296(5), E1085-E1092.
5. Ionescu M, Bhatt DL (2006). Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab, 91(12), 4792-4797.